胎儿LAK/IL—2治疗长期HBV无症状携带者的临床研究

Clinical Study on Long-term HBV Asymptomatic Carriers Treated with Fetal Spleenocyte LAK/IL-2

应用胎儿脾LAK细胞,配合rIL—2和rIFN—γ治疗8例长期HBV无症状携带者,结果表明:有75％(6/8)的患者HBeAg转阴,其中有25％(2/8)的患者HBeAg和HBsAg均转阴。治疗后CD_8^+T细胞稍有增高(P<0.05),Tac抗原比治疗前和对照组均显著增高(P<0.01),血清sIL—2R,IL—8和TNF—α治疗后均显著增高(P<0.01)。结果提示:LAK/IL—2和IFN—γ过继免疫治疗可以抑制HBV复制或协助机体清除HBV。其现理可能是联合调整机体免疫系统的结果。

8 cases of long-term asymptomatic hepatitis B virus(HBV)carriers were treated with lymphokine actiat-ed killer(LAK)cells from fetal spleenocytes induced by interleukin 2 inv itro,combined with IL-2 and IFN -γ. The results showed that:75% (6/8) of them lossed serum HBeAg ,25% (2/8)of them appeared HBeAg and HBsAg conversion;the percentage of CD8+ T lymphocytes increased after therapy (P<0. 05). expression of Tac antigen on PBMC from them increased significantly as compared with that before treatment and normal controls (P<0.01 ) ; soluble IL-2 receptor (sIL-2R) IL-8 and TNF -α in serum of them significantly increased (P<0. 01 ). The results indicated that adoptive immunotherapy using LAK/IL-2 and IFN -γ could inhibit HBV replication and/or help to clean HBV from the patients. The mechanism of the clearance HBV might be a results of effect associated by LAK ,IL-2,IFN-γ and in vivo immune system.